Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 86


Ophthalmic statistics note 13: method agreement studies in ophthalmology-please don't carry on correlating….

Bunce C, Stratton IM, Elders A, Czanner G, Doré C, Freemantle N; Ophthalmic Statistics Group.

Br J Ophthalmol. 2019 Sep;103(9):1201-1203. doi: 10.1136/bjophthalmol-2018-313759. Epub 2019 Jul 18. No abstract available.


Individualised screening for diabetic retinopathy: the ISDR study-rationale, design and methodology for a randomised controlled trial comparing annual and individualised risk-based variable-interval screening.

Broadbent DM, Sampson CJ, Wang A, Howard L, Williams AE, Howlin SU, Appelbe D, Moitt T, Cheyne CP, Rahni MM, Kelly J, Collins J, García-Fiñana M, Stratton IM, James M, Harding SP; ISDR Study Group.

BMJ Open. 2019 Jun 17;9(6):e025788. doi: 10.1136/bmjopen-2018-025788.


Cost-effectiveness of digital surveillance clinics with optical coherence tomography versus hospital eye service follow-up for patients with screen-positive maculopathy.

Leal J, Luengo-Fernandez R, Stratton IM, Dale A, Ivanova K, Scanlon PH.

Eye (Lond). 2019 Apr;33(4):640-647. doi: 10.1038/s41433-018-0297-7. Epub 2018 Nov 30.


Utility of HbA1c assessment in people with diabetes awaiting liver transplantation.

Bhattacharjee D, Vracar S, Round RA, Nightingale PG, Williams JA, Gkoutos GV, Stratton IM, Parker R, Luzio SD, Webber J, Manley SE, Roberts GA, Ghosh S.

Diabet Med. 2019 Nov;36(11):1444-1452. doi: 10.1111/dme.13870. Epub 2019 Apr 30.


Personalized risk-based screening for diabetic retinopathy: A multivariate approach versus the use of stratification rules.

García-Fiñana M, Hughes DM, Cheyne CP, Broadbent DM, Wang A, Komárek A, Stratton IM, Mobayen-Rahni M, Alshukri A, Vora JP, Harding SP.

Diabetes Obes Metab. 2019 Mar;21(3):560-568. doi: 10.1111/dom.13552. Epub 2018 Oct 30.


Individualised variable-interval risk-based screening for sight-threatening diabetic retinopathy: the Liverpool Risk Calculation Engine.

Eleuteri A, Fisher AC, Broadbent DM, García-Fiñana M, Cheyne CP, Wang A, Stratton IM, Gabbay M, Seddon D, Harding SP; Individualised Screening for Diabetic Retinopathy (ISDR) Study Group.

Diabetologia. 2017 Nov;60(11):2174-2182. doi: 10.1007/s00125-017-4386-0. Epub 2017 Aug 24.


Factors determining uptake of diabetic retinopathy screening in Oxfordshire.

Moreton RBR, Stratton IM, Chave SJ, Lipinski H, Scanlon PH.

Diabet Med. 2017 Jul;34(7):993-999. doi: 10.1111/dme.13350. Epub 2017 Apr 10.


Risk of diabetic retinopathy at first screen in children at 12 and 13 years of age.

Scanlon PH, Stratton IM, Bachmann MO, Jones C, Leese GP; Four Nations Diabetic Retinopathy Screening Study Group.

Diabet Med. 2016 Dec;33(12):1655-1658. doi: 10.1111/dme.13263. Epub 2016 Oct 19.


Data from UK Biobank on febrile illness.

Stratton IM.

Eye (Lond). 2016 Dec;30(12):1650-1651. doi: 10.1038/eye.2016.200. Epub 2016 Sep 16. No abstract available.


Can HbA1c detect undiagnosed diabetes in acute medical hospital admissions?

Manley SE, O'Brien KT, Quinlan D, Round RA, Nightingale PG, Ali F, Durrani BK, Liew A, Luzio SD, Stratton IM, Roberts GA.

Diabetes Res Clin Pract. 2016 May;115:106-14. doi: 10.1016/j.diabres.2016.01.023. Epub 2016 Jan 21.


The use of statistical methodology to determine the accuracy of grading within a diabetic retinopathy screening programme.

Oke JL, Stratton IM, Aldington SJ, Stevens RJ, Scanlon PH.

Diabet Med. 2016 Jul;33(7):896-903. doi: 10.1111/dme.13053. Epub 2016 Jan 10. Erratum in: Diabet Med. 2019 Oct;36(10):1319.


Response to Comment on Leese et al. Progression of Diabetes Retinal Status Within Community Screening Programs and Potential Implications for Screening Intervals. Diabetes Care 2015;38:488-494.

Leese GP, Stratton IM, Land M, Bachmann MO, Jones C, Scanlon P, Looker HC, Ferguson B; Four Nations Diabetic Retinopathy Screening Study Group.

Diabetes Care. 2015 Dec;38(12):e209-10. doi: 10.2337/dci15-0015. No abstract available.


Menopausal Status and Abdominal Obesity Are Significant Determinants of Hepatic Lipid Metabolism in Women.

Hodson L, Banerjee R, Rial B, Arlt W, Adiels M, Boren J, Marinou K, Fisher C, Mostad IL, Stratton IM, Barrett PH, Chan DC, Watts GF, Harnden K, Karpe F, Fielding BA.

J Am Heart Assoc. 2015 Oct 2;4(10):e002258. doi: 10.1161/JAHA.115.002258.


Development of a cost-effectiveness model for optimisation of the screening interval in diabetic retinopathy screening.

Scanlon PH, Aldington SJ, Leal J, Luengo-Fernandez R, Oke J, Sivaprasad S, Gazis A, Stratton IM.

Health Technol Assess. 2015 Sep;19(74):1-116. doi: 10.3310/hta19740.


Screening attendance, age group and diabetic retinopathy level at first screen.

Scanlon PH, Stratton IM, Leese GP, Bachmann MO, Land M, Jones C, Ferguson B; Four Nations Diabetic Retinopathy Screening Study Group.

Diabet Med. 2016 Jul;33(7):904-11. doi: 10.1111/dme.12957. Epub 2015 Oct 6.


Progression of diabetes retinal status within community screening programs and potential implications for screening intervals.

Leese GP, Stratton IM, Land M, Bachmann MO, Jones C, Scanlon P, Looker HC, Ferguson B; Four Nations Diabetic Retinopathy Screening Study Group.

Diabetes Care. 2015 Mar;38(3):488-94. doi: 10.2337/dc14-1778. Epub 2014 Dec 18.


The use of weighted health-related Quality of Life scores in people with diabetic macular oedema at baseline in a randomized clinical trial.

Scanlon PH, Loftus J, Starita C, Stratton IM.

Diabet Med. 2015 Jan;32(1):97-101. doi: 10.1111/dme.12593. Epub 2014 Oct 13.


Differences in level of confidence in diabetes care between different groups of trainees: the TOPDOC diabetes study.

Smith CJ, George JT, Warriner D, McGrane DJ, Rozario KS, Price HC, Wilmot EG, Kar P, Stratton IM, Jude EB, McKay GA.

BMC Med Educ. 2014 Sep 17;14:191. doi: 10.1186/1472-6920-14-191.


Influence of primary care practices on patients' uptake of diabetic retinopathy screening: a qualitative case study.

Lindenmeyer A, Sturt JA, Hipwell A, Stratton IM, Al-Athamneh N, Gadsby R, O'Hare JP, Scanlon PH.

Br J Gen Pract. 2014 Aug;64(625):e484-92. doi: 10.3399/bjgp14X680965.


Comparison of IFCC-calibrated HbA(1c) from laboratory and point of care testing systems.

Manley SE, Hikin LJ, Round RA, Manning PW, Luzio SD, Dunseath GJ, Nightingale PG, Stratton IM, Cramb R, Sikaris KA, Gough SC, Webber J.

Diabetes Res Clin Pract. 2014 Sep;105(3):364-72. doi: 10.1016/j.diabres.2014.05.003. Epub 2014 May 23.


Epidemiological issues in diabetic retinopathy.

Scanlon PH, Aldington SJ, Stratton IM.

Middle East Afr J Ophthalmol. 2013 Oct-Dec;20(4):293-300. doi: 10.4103/0974-9233.120007. Review.


Agreement between photographic screening and hospital biomicroscopy grading of diabetic retinopathy and maculopathy.

Healy R, Sallam A, Jones V, Donachie PH, Scanlon PH, Stratton IM, Johnston RL.

Eur J Ophthalmol. 2014 Jul-Aug;24(4):550-8. doi: 10.5301/ejo.5000404. Epub 2013 Dec 9.


Delay in diabetic retinopathy screening increases the rate of detection of referable diabetic retinopathy.

Scanlon PH, Aldington SJ, Stratton IM.

Diabet Med. 2014 Apr;31(4):439-42. doi: 10.1111/dme.12313. Epub 2013 Oct 17.


Updating diabetic retinopathy screening lists using automatic extraction from GP patient records.

Scanlon PH, Provins EK, Craske S, Chave SJ, Aldington SJ, Martin CN, Stratton IM.

J Med Screen. 2013;20(3):111-7. doi: 10.1177/0969141313505747. Epub 2013 Sep 24.


Risk stratification for diabetic eye screening.

Stratton IM, Aldington SJ.

Diabetologia. 2014 Jan;57(1):259. doi: 10.1007/s00125-013-3060-4. Epub 2013 Sep 22. No abstract available.


United Kingdom National Ophthalmology Database Study: Diabetic Retinopathy; Report 1: prevalence of centre-involving diabetic macular oedema and other grades of maculopathy and retinopathy in hospital eye services.

Keenan TD, Johnston RL, Donachie PH, Sparrow JM, Stratton IM, Scanlon P.

Eye (Lond). 2013 Dec;27(12):1397-404. doi: 10.1038/eye.2013.196. Epub 2013 Sep 20.


The influence of background diabetic retinopathy in the second eye on rates of progression of diabetic retinopathy between 2005 and 2010.

Scanlon PH, Stratton IM, Histed M, Chave SJ, Aldington SJ.

Acta Ophthalmol. 2013 Aug;91(5):e335-9. doi: 10.1111/aos.12074. Epub 2013 Apr 1.


Which visual acuity measurements define high-quality care for patients with neovascular age-related macular degeneration treated with ranibizumab?

Ross AH, Donachie PH, Sallam A, Stratton IM, Mohamed Q, Scanlon PH, Kirkpatrick JN, Johnston RL.

Eye (Lond). 2013 Jan;27(1):56-64. doi: 10.1038/eye.2012.225. Epub 2012 Nov 23.


A simple risk stratification for time to development of sight-threatening diabetic retinopathy.

Stratton IM, Aldington SJ, Taylor DJ, Adler AI, Scanlon PH.

Diabetes Care. 2013 Mar;36(3):580-5. doi: 10.2337/dc12-0625. Epub 2012 Nov 12.


Diabetic CVI figures for England and Wales (2007-2009).

Bunce C, Stratton IM, Cohen S.

Br J Ophthalmol. 2012 Jul;96(7):1046-7. doi: 10.1136/bjophthalmol-2012-301813. Epub 2012 Apr 21. No abstract available.


Lack of confidence among trainee doctors in the management of diabetes: the Trainees Own Perception of Delivery of Care (TOPDOC) Diabetes Study.

George JT, Warriner D, McGrane DJ, Rozario KS, Price HC, Wilmot EG, Kar P, Stratton IM, Jude EB, McKay GA; TOPDOC Diabetes Study Team.

QJM. 2011 Sep;104(9):761-6. doi: 10.1093/qjmed/hcr046. Epub 2011 Apr 21.


Agreement and reasons for disagreement between photographic and hospital biomicroscopy grading of diabetic retinopathy.

Sallam A, Scanlon PH, Stratton IM, Jones V, Martin CN, Brelen M, Johnston RL.

Diabet Med. 2011 Jun;28(6):741-6. doi: 10.1111/j.1464-5491.2011.03273.x.


Validation of an algorithm combining haemoglobin A(1c) and fasting plasma glucose for diagnosis of diabetes mellitus in UK and Australian populations.

Manley SE, Sikaris KA, Lu ZX, Nightingale PG, Stratton IM, Round RA, Baskar V, Gough SC, Smith JM.

Diabet Med. 2009 Feb;26(2):115-21. doi: 10.1111/j.1464-5491.2008.02652.x.


Atorvastatin in Factorial with Omega-3 EE90 Risk Reduction in Diabetes (AFORRD): a randomised controlled trial.

Holman RR, Paul S, Farmer A, Tucker L, Stratton IM, Neil HA; Atorvastatin in Factorial with Omega-3 EE90 Risk Reduction in Diabetes Study Group.

Diabetologia. 2009 Jan;52(1):50-9. doi: 10.1007/s00125-008-1179-5. Epub 2008 Nov 11.


Prevalence of GCK mutations in individuals screened for fasting hyperglycaemia.

Gloyn AL, van de Bunt M, Stratton IM, Lonie L, Tucker L, Ellard S, Holman RR.

Diabetologia. 2009 Jan;52(1):172-4. doi: 10.1007/s00125-008-1188-4. Epub 2008 Nov 11. No abstract available.


Preanalytical, analytical, and computational factors affect homeostasis model assessment estimates.

Manley SE, Luzio SD, Stratton IM, Wallace TM, Clark PM.

Diabetes Care. 2008 Sep;31(9):1877-83. doi: 10.2337/dc08-0097. Epub 2008 Jun 5.


Recommendations for designing tables that report randomized trials.

Johnson ES, Stratton IM.

Diabet Med. 2007 Dec;24(12):1309-12. Epub 2007 Nov 1. No abstract available.


A method for assessing quality of control from glucose profiles.

Hill NR, Hindmarsh PC, Stevens RJ, Stratton IM, Levy JC, Matthews DR.

Diabet Med. 2007 Jul;24(7):753-8. Epub 2007 Apr 19.


Comparison of 11 human insulin assays: implications for clinical investigation and research.

Manley SE, Stratton IM, Clark PM, Luzio SD.

Clin Chem. 2007 May;53(5):922-32. Epub 2007 Mar 15.


Additive effects of glycaemia and blood pressure exposure on risk of complications in type 2 diabetes: a prospective observational study (UKPDS 75).

Stratton IM, Cull CA, Adler AI, Matthews DR, Neil HA, Holman RR.

Diabetologia. 2006 Aug;49(8):1761-9. Epub 2006 May 31.


How to ensure your paper is rejected by the statistical reviewer.

Stratton IM, Neil A.

Diabet Med. 2005 Apr;22(4):371-3. Review. No abstract available.


Islet autoantibodies in clinically diagnosed type 2 diabetes: prevalence and relationship with metabolic control (UKPDS 70).

Davis TM, Wright AD, Mehta ZM, Cull CA, Stratton IM, Bottazzo GF, Bosi E, Mackay IR, Holman RR.

Diabetologia. 2005 Apr;48(4):695-702. Epub 2005 Feb 24.


Insulin sensitivity at diagnosis of Type 2 diabetes is not associated with subsequent cardiovascular disease (UKPDS 67).

Adler AI, Levy JC, Matthews DR, Stratton IM, Hines G, Holman RR.

Diabet Med. 2005 Mar;22(3):306-11.


Risks of progression of retinopathy and vision loss related to tight blood pressure control in type 2 diabetes mellitus: UKPDS 69.

Matthews DR, Stratton IM, Aldington SJ, Holman RR, Kohner EM; UK Prospective Diabetes Study Group.

Arch Ophthalmol. 2004 Nov;122(11):1631-40.


A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68).

Clarke PM, Gray AM, Briggs A, Farmer AJ, Fenn P, Stevens RJ, Matthews DR, Stratton IM, Holman RR; UK Prospective Diabetes Study (UKDPS) Group.

Diabetologia. 2004 Oct;47(10):1747-59. Epub 2004 Oct 27.


Risk factors for myocardial infarction case fatality and stroke case fatality in type 2 diabetes: UKPDS 66.

Stevens RJ, Coleman RL, Adler AI, Stratton IM, Matthews DR, Holman RR.

Diabetes Care. 2004 Jan;27(1):201-7.


Apolipoprotein E genotype, islet amyloid deposition and severity of Type 2 diabetes.

Powell DS, Maksoud H, Chargé SB, Moffitt JH, Desai M, Da Silva Fihlo RL, Hattersley AT, Stratton IM, Matthews DR, Levy JC, Clark A.

Diabetes Res Clin Pract. 2003 May;60(2):105-10.


UKPDS58--modeling glucose exposure as a risk factor for photocoagulation in type 2 diabetes.

Stevens RJ, Stratton IM, Holman RR; UK Prospective Diabetes Study (UKPDS58).

J Diabetes Complications. 2002 Nov-Dec;16(6):371-6.


UKPDS 60: risk of stroke in type 2 diabetes estimated by the UK Prospective Diabetes Study risk engine.

Kothari V, Stevens RJ, Adler AI, Stratton IM, Manley SE, Neil HA, Holman RR.

Stroke. 2002 Jul;33(7):1776-81.


Supplemental Content

Loading ...
Support Center